Dementia & neuropsychologia · 2025
Current evidence on drug therapy for dementia in people with Down syndrome: an overview of systematic reviews.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
do Nascimento Ticiano Gomes, do Nascimento Ana Clara Lira, Campos Maria Abath, Fernandes Raphaella Amanda Maria Leite
Аннотация
UNLABELLED: Individuals with Down syndrome (DS) are at a higher risk of developing dementia at an earlier age. Identifying and summarizing studies that provide strong evidence in drug therapy is crucial for aiding healthcare professionals in clinical decision-making.
OBJECTIVE: To identify systematic reviews (SRs) published in various databases and evaluate the effectiveness of pharmacological interventions for treating dementia specifically in individuals with DS.
METHODS: SRs published in the United States National Library of Medicine (PubMed), Scopus, Web of Science, Biblioteca Virtual em Saúde (BVS), and Cochrane Library over the past ten years were included. The methodological quality of the SRs was assessed using the AMSTAR-2 and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tools.
RESULTS: Five SRs were included, analyzing the effects of simvastatin, antioxidants, acetyl-L-carnitine, anticonvulsants, acetylcholinesterase inhibitors (donepezil), NMDA receptor antagonists (memantine), and fast-acting intranasal insulin on dementia symptoms in DS patients.
CONCLUSION: All SRs indicated low - or less - certainty of evidence, suggesting that various pharmacological approaches should be interpreted with caution.
OBJECTIVE: To identify systematic reviews (SRs) published in various databases and evaluate the effectiveness of pharmacological interventions for treating dementia specifically in individuals with DS.
METHODS: SRs published in the United States National Library of Medicine (PubMed), Scopus, Web of Science, Biblioteca Virtual em Saúde (BVS), and Cochrane Library over the past ten years were included. The methodological quality of the SRs was assessed using the AMSTAR-2 and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tools.
RESULTS: Five SRs were included, analyzing the effects of simvastatin, antioxidants, acetyl-L-carnitine, anticonvulsants, acetylcholinesterase inhibitors (donepezil), NMDA receptor antagonists (memantine), and fast-acting intranasal insulin on dementia symptoms in DS patients.
CONCLUSION: All SRs indicated low - or less - certainty of evidence, suggesting that various pharmacological approaches should be interpreted with caution.